Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Net Income towards Common Stockholders (2022 - 2023)

Historic Net Income towards Common Stockholders for Lexeo Therapeutics (LXEO) over the last 2 years, with Q4 2023 value amounting to -$14.2 million.

  • Lexeo Therapeutics' Net Income towards Common Stockholders rose 267.54% to -$14.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$66.4 million, marking a year-over-year change of. This contributed to the annual value of -$98.3 million for FY2024, which is 4810.53% down from last year.
  • Latest data reveals that Lexeo Therapeutics reported Net Income towards Common Stockholders of -$14.2 million as of Q4 2023, which was up 267.54% from -$20.1 million recorded in Q3 2023.
  • Lexeo Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$13.4 million during Q2 2023, with a 5-year trough of -$20.1 million in Q3 2023.